Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology.

Sgarra L, Addabbo F, Potenza MA, Montagnani M.

Am J Physiol Endocrinol Metab. 2012 May 1;302(10):E1171-82. doi: 10.1152/ajpendo.00038.2012. Epub 2012 Feb 28.

2.

Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.

Krentz A.

Diabetes Metab Res Rev. 2009 Feb;25(2):112-26. doi: 10.1002/dmrr.937. Review.

PMID:
19219860
3.

Rationale and design of the Glitazones and the Endothelium (GATE) study: evaluation of rosiglitazone on endothelial function in patients with diabetes.

Hubacek J, Verma S, Shewchuk L, Ross SJ, Edwards A, Anderson TJ.

Can J Cardiol. 2004 Dec;20(14):1449-53.

PMID:
15614340
4.

Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.

Abdin AA, Baalash AA, Hamooda HE.

J Diabetes Complications. 2010 May-Jun;24(3):168-78. doi: 10.1016/j.jdiacomp.2009.01.005. Epub 2009 Mar 27.

PMID:
19328014
5.

Rosiglitazone: potential beneficial impact on cardiovascular disease.

Viberti GC.

Int J Clin Pract. 2003 Mar;57(2):128-34. Review.

PMID:
12661797
6.

Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.

Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB.

Pharmacotherapy. 2006 Feb;26(2):168-81. Review.

PMID:
16466323
7.

Reassessing the cardiovascular risks and benefits of thiazolidinediones.

Zinn A, Felson S, Fisher E, Schwartzbard A.

Clin Cardiol. 2008 Sep;31(9):397-403. doi: 10.1002/clc.20312. Review.

8.

Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.

Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A, Maerz W, Hombach V, Koenig W.

Circulation. 2003 Apr 22;107(15):1954-7. Epub 2003 Apr 14.

9.

Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.

Dandona P, Aljada A.

J Diabetes Complications. 2004 Mar-Apr;18(2):91-102. Review.

PMID:
15120703
10.
11.
12.

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

Eur J Pharmacol. 2008 Apr 14;584(1):192-201. doi: 10.1016/j.ejphar.2007.12.036. Epub 2008 Feb 14.

PMID:
18346728
13.

Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update.

Sarafidis PA.

Fundam Clin Pharmacol. 2008 Jun;22(3):247-64. doi: 10.1111/j.1472-8206.2008.00568.x. Epub 2008 Apr 15. Review.

PMID:
18422634
14.

Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.

Ratner RE, Cannon CP, Gerstein HC, Nesto RW, Serruys PW, Van Es GA, Kolatkar NS, Kravitz BG, Zalewski A, Fitzgerald PJ; APPROACH Study Group.

Am Heart J. 2008 Dec;156(6):1074-9. doi: 10.1016/j.ahj.2008.07.025. Epub 2008 Oct 11.

PMID:
19033001
15.

The cardiovascular safety of rosiglitazone.

Ajjan RA, Grant PJ.

Expert Opin Drug Saf. 2008 Jul;7(4):367-76. doi: 10.1517/14740338.7.4.367 . Review.

PMID:
18613801
16.

Metformin and pioglitazone: Effectively treating insulin resistance.

Staels B.

Curr Med Res Opin. 2006;22 Suppl 2:S27-37. Review.

PMID:
16914073
17.

The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.

Sarafidis PA, Lasaridis AN, Nilsson PM, Mouslech TF, Hitoglou-Makedou AD, Stafylas PC, Kazakos KA, Yovos JG, Tourkantonis AA.

Metabolism. 2005 Sep;54(9):1236-42.

PMID:
16125536
18.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
19.

Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.

Cavender MA, Lincoff AM.

Am J Cardiovasc Drugs. 2010;10(4):209-16. doi: 10.2165/11539500-000000000-00000.

PMID:
20653327
20.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014

Supplemental Content

Support Center